Lawmakers Introduced Bills to Update Biosimilar Pricing
New legislation aims to clarify Medicare negotiation rules, affecting manufacturers and healthcare providers.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should government policy prioritize lower drug prices through Medicare negotiations even if it risks innovation competition?
Members of Congress introduced H.R.10628 and S.5571 to address uncertainty regarding biosimilar eligibility for Medicare price negotiations. The proposed updates aim to streamline market entry as 118 biologics face expiring patent protections over the next decade.
Why it matters
Current policy uncertainty hinders the predictability required by manufacturers to commit the $300 million typically needed for biosimilar development. Providing clearer regulatory pathways is intended to help capture projected savings of $181 billion over the next five years.
Biosimilars are on average 50 percent lower-cost than reference biologics, with $56 billion in savings generated to date. However, developing these drugs requires up to nine years and costs as much as $300 million per product.
The players
House of Representatives
The lower chamber of the United States Congress responsible for federal legislative and budgetary rulemaking.
Senate
The upper chamber of the United States Congress that shares authority over federal policy and regulatory oversight.
The details
The proposed legislation seeks to codify clear eligibility criteria for biosimilars to participate in Medicare price negotiations, reducing the current regulatory ambiguity. By streamlining this process, the bills intend to incentivize investment in biosimilar alternatives to costly biologics. Operators in the pharmaceutical and healthcare sectors should monitor how these rules might accelerate the entry of lower-cost competitors into the market.
Timeline
118 biologics are projected to lose patent protection over the next decade.
Potential biosimilar savings are expected to grow to $181 billion over the next five years.
Market Landscape
This legislative push follows the Inflation Reduction Act's Medicare drug-price negotiation provisions, which fundamentally altered drug pricing dynamics. These new bills aim to rectify market entry barriers that could otherwise dampen the competitive impact of that existing law.
Healthcare operators and pharmacy managers should monitor the legislative progress of these bills to anticipate shifts in drug procurement costs. Owners should review their clinical supply strategies to account for the potential faster adoption of lower-cost biosimilar alternatives.
The takeaway
The proposed changes represent a critical effort to stabilize investment conditions for biosimilar developers. Track the progress of H.R.10628 and S.5571 to assess when these regulatory adjustments might begin impacting your organization’s drug purchasing costs.
Further reading
For more on evolving drug policy and market dynamics, visit Healthcare.
More information
For additional insights on the market, view the Biosimilars Forum information and resources.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should government policy prioritize lower drug prices through Medicare negotiations even if it risks innovation competition?
